

One bioinformatics pipeline for genomic characterisation of *Candida* sp. clinical strains

Carvalho MJ¹, Silva C¹, Guimarães R¹, Bezerra R¹, Pinheiro M¹, Santos MA¹, Moura G¹

¹ Institute of Biomedicine- iBiMED, Department of Medical Sciences, University of Aveiro

Candida sp. are the most common cause of fungal infections [1]. The increase of *Candida* antifungal resistance to the most widely used antifungals is alarming, given persistent infections are common and may be left untreated [2]. Genomic surveillance of *Candida* isolates allows for the investigation of the biology, ecology, phylogenomics and epidemiology of these pathogens. Importantly, the genomic characterisation of *Candida* isolates provides accurate species identification, monitoring of antifungal resistance, and the surveillance of the emergence of novel pathogens, which are crucial for appropriate diagnostic and treatment [3].

On the other hand, as eukaryotic unicellular organisms, *Candida* sp. present specific genomic characteristics that distinguish them from the most commonly studied genomes, i.e., bacteria and human. In this way, many of the open-source bioinformatic tools becomes inappropriate to tackle fungal genomes as needed, which hinders this type of analyses and delays their application to the clinical setting. Furthermore, Oxford Nanopore Technologies have been presented as an easy-to-use sequencing methodology in the clinical setting [4], but ONT-dedicated bioinformatic pipelines aiming to analyse and extract useful information from fungal genomes collected during infection are still lacking.

In this work, we have addressed this issue, and propose a bioinformatics pipeline to conduct isolates identification and variant analysis of fungal species with clinical relevance, starting with raw data from MinION sequencing of whole genomes of ten *Candida* sp. isolates from vaginal, oral and blood samples. Our results show the importance of genomic surveillance for the accurate identification of pathogens and understanding the adaptability of isolates to particular niches. Future work involves Illumina sequencing of these genomes for hybrid assembly/read correction and improvement of our analysis pipeline.

CANCYL-POCI-01-0145-FEDER-031849 is supported by the Operational Program POCI, in its FEDER/FNR component, and the Foundation for Science and Technology, in its State Budget component. GenomePT POCI-01-0145-FEDER-022184; PBE POCI-01-0145-FEDER-031238; iBiMED UIDP/04501/2020-Programático

[1] doi: 10.1101/cshperspect.a019778

[2] doi: 10.1093/ofid/ofy358

[3] doi: 10.1038/s41426-018-0045-x

[4] <https://nanoporetech.com/applications/clinical-research> (last accessed 20210407)

Genomic characterisation of *Candida albicans* clinical isolates

Carvalho MJ, Silva C, Guimarães R, Bezerra R,

Pinheiro M, Santos MAS, Moura G

Institute of Biomedicine, University of Aveiro

mjcarvalho@ua.pt



7th May 2021

universidade de aveiro



ibimed

instituto de biomedicina



Acknowledgments

Moura & Santos Lab (iBiMED – Universidade de Aveiro)

Andreia Reis (iBiGEN – Universidade de Aveiro)

Patrícia Arinto (iBiGEN – Universidade de Aveiro)

Sofia Marques (iBiGEN – Universidade de Aveiro)

Carla Oliveira (iBiMED – Universidade de Aveiro)

Inês Sousa (iBiMED – Universidade de Aveiro)

Ana Poim (iBiMED – Universidade de Aveiro)

Dr Ana Paula Sampaio (CBMA – Universidade do Minho)

Dr Célia Pais (CBMA – Universidade do Minho)



Thank you

CANCYL-POCI-01-0145-FEDER-031849 is supported by the Operational Program POCI, in its FEDER/FNR component, and the Foundation for Science and Technology, in its State Budget component. GenomePT POCI-01-0145-FEDER-022184; PBE POCI-01-0145-FEDER-031238; iBiMED UIDP/04501/2020-Programático